1. HBW Insight
  2. >>Geography
  3. >>North America

Much At Stake In Pending 'Natural' Class Action Appeals

 
• By Ryan Nelson

A number of proposed class actions concerning "natural" food claims are pending in the Ninth Circuit, following lower court decisions dismissing the suits, denying class certification and/or granting summary judgment to defendants. Their outcomes could be significant in shaping the course of related litigation going forward in the supplement and personal care industries.

Class action defendants and other industry stakeholders are watching how appeals play out in the federal Ninth Circuit regarding alleged deception in "natural" food claims, which could have significant bearing on cases going forward across consumer-packaged-goods sectors.

In an interview, Dale Giali, a partner at Mayer Brown LLP in Los Angeles, identified a number of false advertising...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

More from North America

Washington State TFCA Violators Likely To Face Conversation Before Penalties – DOE

 
• By Eileen Francis

The Washington State Department of Ecology will try to work with companies that violate the Toxic Free Cosmetics Act, rather than reflexively imposing the $5,000-per-violation fine for first-time offenders, says the law’s implementation planner. She noted financial assistance is available for small businesses, as well as incentives for companies adopting measures “beyond compliance.”

Adcomm Reform: Getting Needed Information More Important Than Vote Or Discussion

 
• By Derrick Gingery

US FDA Office of New Drugs Director Peter Stein says review divisions have made the case that a discussion-only meeting would solicit the necessary input.

US FDA’s Petition Procedures No Place For OTC Acetaminophen Pediatric Dosing Enforcement

 
• By Malcolm Spicer

Requests for “enforcement actions are not within the scope of FDA’s citizen petition procedures,” CDER says, rejecting petition dosing device firm Parenteral Technologies submitted as it prepares for workshop on Pediatric Research Equity Act requirements for OTC NDA sponsors.